An evaluation of the additive effect of natural herbal medicine on SARS or SARS-like infectious diseases in 2003: A randomized, double-blind, and controlled pilot study

Evidence-based Complementary and Alternative Medicine

Volumn 5, Issue 3, 2008, Pages 355-362

  Hsu, Chung Hua ^a,b   Hwang, Kung Chang ^c   Chao, Chung Liang ^d   Chang, Steve G N ^b   Ho, Mei Shang ^e   Lin, Jaung Geng ^f   Chang, Hen Hong ^g   Kao, Shung Te ^f   Chen, Yi Ming ^a   Chou, Pesus ^a,h  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI HOSPITAL   (Taiwan)

^c Bali Mental Hospital   (Taiwan)

^d Chia yi Hospital   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

^h NONE   (Taiwan)

Author keywords

Avian influenza; Nature herbal medicine; SARS

Indexed keywords

CLARITHROMYCIN; HERBACEOUS AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE SODIUM SUCCINATE; PLACEBO; RIBAVIRIN; ROBATROL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGARICUS BRAZEI; AGASTACHE RUGOSA; ARTICLE; AVIAN INFLUENZA; BUPLEURUM CHINENESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORDYCEPS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SCREENING; ELIXIR; FEMALE; GARDENIAE JASMINOIDES; GINSENG; GYPSUM FIBROSUM; HUMAN; IMAGE ANALYSIS; INFECTION; INFECTION CONTROL; LUNG INFILTRATE; MALE; MEDICINAL PLANT; NOTOPTERYGIUM INCISIUM; OPHIOPOGON JAPONICUS; OUTCOME ASSESSMENT; PAEONIAE LACTIFLORAE; PILOT STUDY; PINELLIA TERNATA; PLATYCODON GRANDIFLORUM; PORIA COCOS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZONEPETA TENUIFOLIA; SCORING SYSTEM; SCUTELLARIA BAICALENSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SILER DIVARICATUM; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; WORLD HEALTH ORGANIZATION;

EID: 51849095507     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem035     Document Type: Article

References (30)

1. World Health Organization. Update 96 - Taiwan, China SARS transmission interrupted in last outbreak area. Available at: http//www.who.int./csr/ sarscountry/2003_07_05/en/. (last accessed July 15, 2003).
2. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: http//www.who.int./ csr/sarscountry/2003_09_26/en/. (last accessed September 30, 2003).
3. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus association with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.
5. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25.
6. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:1-9.
7. Ho W. Guidelines on management of severe acute respiratory syndrome (SARS). Lancet 2003;361:1313-5.
8. So LKY, Lau ACW, Yam LYC, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-7.
9. World Health Organization. Case definitions for surveillance of severe acute respiratory syndrome (SARS). Available at: http//www.who.int./csr/ casedefinition/en. (last accessed April 22, 2003).
10. Sorimachi K, Ikehara Y, Maezato G, Okubo A, Yamazaki S, Akimoto K, et al. Inhibition by Agaricus brazei Murill fractions of cytopathic effect induced by western equine encephalitis virus on VERO cell in vitro Biosci, Biotechnoi Biochem 2001;65:1645-7.
11. Nakajima A, Ishida T, Koga M, Takeuchi T, Mazda O, Takeuchi M, et al. Effect of hot water extract from Agaricus brazei Murill on antibody-production cell in mice. Int Immunopharmacol 2002;2:1205-11.
12. Chen L, Shao HJ, Su YB. Coimmunization of Agaricus brazei Murill extract with hepatitis B virus core protein through DNA vaccine enhances cellular and humoral immune response. Int Immunopharmacol 2004;4:403-9.
13. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
14. Avendano M, Derkach P, Swan S. Clinical course and management in health care workers in Toronto: a case series. ACMAJ 2003;168:1-13.
15. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263-70.
16. From the CDC. Updated Interim Surveillance Case Definition for Severe Respiratory Syndrome (SARS)-United States, April 29, 2003. JAMA 2003;289:2367-9.
17. From the CDC.. Updated Interim Surveillance Case Definition for Severe Respiratory Syndrome (SARS)-United States, June 11, 2003. JAMA 2003;290:34.
18. Li G, Chen X, Xu A. Profile of specific antibody to the SARS-associated coronavirus. N Engl J Med 2003;349:508-9.
19. Hoey J. Updated SARS case definition using laboratory criteria. CMAJ 2003;168:1566-7.
20. Jia W, Gao W. Is traditional Chinese medicine useful in the treatment of SARS? Phytother Res 2003;17:840-1.
21. Hon KL, Leung CW, Cheng WT, Chan PK, Chu WC, Kwan YW, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003;361:1701-3.
22. Masur H, Ezekiel E, Lane HC. Severe acute respiratory syndrome providing care in face of uncertainty. JAMA 2003;289:10-2.
23. Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, et al. Virological features and clinical manifestations associated with human metalpneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186:1330-4.
24. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
25. Tsang KW, Ho PL, Ool GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
26. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, et al. Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003;58:686-9.
27. Kontoyiannis DP, Pasqualini R, Arap W. Aminopeptidase N inhibitors and SARS. Lancet 2003;361:1558.
28. Chen CN, Lin CPC, Huang KK, Chen WC, Hsieh HP, Liang PH, Hsu JTA. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3?-digallate (TF3). Evid Based Complement Altern Med 2005;2:209-15.
29. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A(H5N1). N Engl J Med 2005;352:338-41.
30. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85.